186 related articles for article (PubMed ID: 12497007)
1. Clinical significance of pulmonary metastases in stage D2 prostate cancer patients.
Nakamachi H; Suzuki H; Akakura K; Imamoto T; Ueda T; Ishihara M; Furuya Y; Ichikawa T; Igarashi T; Ito H
Prostate Cancer Prostatic Dis; 2002; 5(2):159-63. PubMed ID: 12497007
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
3. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
4. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy for clinical T4 prostate cancer.
Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
Behrakis P; Koutsilieris M
Anticancer Res; 1997; 17(3A):1517-8. PubMed ID: 9179189
[TBL] [Abstract][Full Text] [Related]
7. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
8. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer.
Sakao Y; Miyamoto H; Yamazaki A; Oh T; Fukai R; Shiomi K; Saito Y
Ann Thorac Surg; 2006 Jan; 81(1):292-7. PubMed ID: 16368383
[TBL] [Abstract][Full Text] [Related]
10. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer.
Welter S; Jacobs J; Krbek T; Poettgen C; Stamatis G
Eur J Cardiothorac Surg; 2007 Feb; 31(2):167-72. PubMed ID: 17150367
[TBL] [Abstract][Full Text] [Related]
13. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
14. Significance of intramammary lymph nodes in the staging of breast cancer: correlation with tumor characteristics and outcome.
Nassar A; Cohen C; Cotsonis G; Carlson G
Breast J; 2008; 14(2):147-52. PubMed ID: 18248563
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
16. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis.
Riquet M; Assouad J; Bagan P; Foucault C; Le Pimpec Barthes F; Dujon A; Danel C
Ann Thorac Surg; 2005 Jan; 79(1):225-33. PubMed ID: 15620948
[TBL] [Abstract][Full Text] [Related]
17. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
18. [Study of the hormone-refractory prostate cancer clinical practice in an anti-cancer center].
Zufferey L; Roques B; Fléchon A; Droz JP
Bull Cancer; 2001 Dec; 88(12):1213-21. PubMed ID: 11792613
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
20. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]